Entrada Therapeutics, Inc. Financial Ratios
TRDA|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
15.3%
Profit Margin
31.1%
Net Income / Revenue
Asset Turnover
0.56
Revenue / Total Assets
Equity Multiplier
0.88
Total Assets / Equity
Composite: 15.3% (reported: 15.3%)
Profitability
Liquidity
Current Ratio
12.53
Quick Ratio
12.53
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.56
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
+23.7%
+51.5pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.